Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
445.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
42
43
Next >
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
Exploring NASDAQ:VRTX's quality characteristics.
October 30, 2023
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors.
Via
Chartmill
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
October 28, 2023
4x returns in just a decade is quite an attainable result for these companies.
Via
The Motley Fool
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy
October 27, 2023
Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock.
Via
InvestorPlace
Exposures
Product Safety
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
October 20, 2023
Via
Benzinga
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
October 27, 2023
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
October 27, 2023
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next
Via
Benzinga
Exposures
Product Safety
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
October 27, 2023
These companies come from very different industries, but each has businesses that investors may find compelling.
Via
The Motley Fool
2 Healthcare Stocks That Could Make You Richer
October 27, 2023
The need for healthcare is consistent and ongoing, a reality that makes this industry resilient to economic downturns.
Via
The Motley Fool
2 Top Healthcare Stocks Defying the Bear Market
October 26, 2023
These companies are building out their revenue and profit streams, and the proof is in the pudding.
Via
The Motley Fool
This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024
October 26, 2023
This rare disease company is on a roll.
Via
The Motley Fool
IBD's 100 Best ESG Companies For 2023
October 27, 2023
The companies on our list combine high sustainability scores and top stock ratings.
Via
Investor's Business Daily
2 Best Healthcare Stocks to Buy Right Now
October 26, 2023
The healthcare industry is an explosive space full of promising, profitable companies.
Via
The Motley Fool
Vertex Pharmaceuticals: Buy at the High?
October 26, 2023
Vertex shares have been flying high in recent times.
Via
The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
October 26, 2023
Great healthcare businesses are out there and their stocks are ripe for the picking.
Via
The Motley Fool
2 No-Brainer Growth Stocks to Buy Right Now
October 26, 2023
These businesses are thriving and raking in profits.
Via
The Motley Fool
2 Fantastic Growth Stocks to Buy Hand Over Fist
October 26, 2023
These stocks make great bargains today.
Via
The Motley Fool
3 Red-Hot Growth Stocks That Are Still Cheap Buys
October 25, 2023
It's not too late to invest in these great businesses.
Via
The Motley Fool
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
October 24, 2023
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
The Best Stocks to Invest $5,000 In Right Now
October 24, 2023
Today, the following three healthcare players look like fantastic bargains.
Via
The Motley Fool
3 Unstoppable Stocks to Buy Sooner Rather Than Later
October 22, 2023
Now is the time to invest in these great stocks.
Via
The Motley Fool
3 Monster Stocks to Buy Without Any Hesitation
October 20, 2023
These big stocks could become a lot bigger.
Via
The Motley Fool
4 Ways to Grow $100,000 Into $1 Million for Retirement
October 19, 2023
Investing for big-time growth doesn't have to be risky.
Via
The Motley Fool
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
October 19, 2023
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
The Stock Market Is Resilient But How Long Will It Last? Your Mid-October Update
October 17, 2023
We're continuing to see resilience in the US Stock Market in the headwinds of otherwise bearish or bad news, but is this the beginning of a larger rally or may the resiliency come to an end soon?
Via
Talk Markets
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
October 17, 2023
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov
Via
Benzinga
Healthcare Portfolio Focus Stocks
October 16, 2023
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.
Via
Talk Markets
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.